Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 9 studies | 20% ± 4% | |
smooth muscle cell | 8 studies | 20% ± 6% | |
fibroblast | 8 studies | 24% ± 7% | |
goblet cell | 5 studies | 28% ± 11% | |
myofibroblast cell | 5 studies | 21% ± 1% | |
plasma cell | 5 studies | 28% ± 9% | |
type II pneumocyte | 5 studies | 24% ± 13% | |
connective tissue cell | 5 studies | 20% ± 4% | |
enterocyte | 4 studies | 20% ± 2% | |
endothelial cell | 4 studies | 22% ± 4% | |
epithelial cell | 4 studies | 37% ± 11% | |
epithelial cell of proximal tubule | 3 studies | 22% ± 4% | |
mast cell | 3 studies | 21% ± 4% | |
plasmacytoid dendritic cell | 3 studies | 21% ± 5% |
Insufficient scRNA-seq data for expression of HYI at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
adipose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 230 |
bladder | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 504 |
blood vessel | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 705 |
breast | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1118 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
esophagus | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 183 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
heart | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
intestine | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 527 |
kidney | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 901 |
liver | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 406 |
lung | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
muscle | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 430 |
pancreas | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 178 |
peripheral blood | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
prostate | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 502 |
skin | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 472 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
stomach | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 286 |
thymus | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 605 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
uterus | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 459 |
GO_0008150 | Biological process | biological_process |
GO_0046487 | Biological process | glyoxylate metabolic process |
GO_0005575 | Cellular component | cellular_component |
GO_0008903 | Molecular function | hydroxypyruvate isomerase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | HYI |
Protein name | Putative hydroxypyruvate isomerase (EC 5.3.1.22) (Endothelial cell apoptosis protein E-CE1) Hydroxypyruvate isomerase (putative) Putative hydroxypyruvate isomerase (EC 5.3.1.22) |
Synonyms | SB156 HT036 |
Description | FUNCTION: Catalyzes the reversible isomerization between hydroxypyruvate and 2-hydroxy-3-oxopropanoate (also termed tartronate semialdehyde). . FUNCTION: Catalyzes the reversible isomerization between hydroxypyruvate and 2-hydroxy-3-oxopropanoate (also termed tartronate semialdehyde). . FUNCTION: Catalyzes the reversible isomerization between hydroxypyruvate and 2-hydroxy-3-oxopropanoate (also termed tartronate semialdehyde). . FUNCTION: Catalyzes the reversible isomerization between hydroxypyruvate and 2-hydroxy-3-oxopropanoate (also termed tartronate semialdehyde). . FUNCTION: Catalyzes the reversible isomerization between hydroxypyruvate and 2-hydroxy-3-oxopropanoate (also termed tartronate semialdehyde). . |
Accessions | Q5T013 F6UJY9 A0A0A0MTR5 ENST00000487366.5 J9JIE9 ENST00000372432.5 [Q5T013-3] ENST00000372434.5 ENST00000372430 F6UJY1 ENST00000372430.9 [Q5T013-1] E7EWH8 ENST00000372433.5 H0YB18 ENST00000583037.5 ENST00000486909.1 H0YB70 ENST00000470662.5 |